OMCL vs MCK

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus 6. 5% for Omnicell, Inc. (OMCL). McKesson Corporation (MCK) offers the better valuation at 28. 9x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate McKesson Corporation (MCK) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, McKesson Corporation (MCK) is the cheapest at 28.

9x versus Omnicell, Inc. at 987. 8x. On forward P/E, McKesson Corporation is actually cheaper at 19. 1x.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +308.

4%, compared to -68. 7% for Omnicell, Inc. (OMCL). Over 10 years, the gap is even starker: MCK returned +351. 9% versus OMCL's +39. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus Omnicell, Inc. 's 1. 34β — meaning OMCL is approximately 3010% more volatile than MCK relative to the S&P 500.

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus 6. 5% for Omnicell, Inc. (OMCL). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 14. 9% year-over-year, compared to -83. 6% for Omnicell, Inc.. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

McKesson Corporation (MCK) is the more profitable company, earning 0.

9% net margin versus 0. 2% for Omnicell, Inc. — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 2% versus 0. 4% for OMCL. At the gross margin level — before operating expenses — OMCL leads at 42. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, McKesson Corporation (MCK) trades at 19.

1x forward P/E versus 22. 6x for Omnicell, Inc. — 3. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MCK: 35. 3% to $1006. 50.

In this comparison, MCK (0.

4% yield) pays a dividend. OMCL does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), +351. 9% 10Y return). Both have compounded well over 10 years (MCK: +351. 9%, OMCL: +39. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OMCL is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.